What Cagrilintide Actually Does in the Body

Cagrilintide is an investigational compound from Novo Nordisk, a long-acting synthetic version of amylin, a hormone the pancreas normally releases alongside insulin. It has not been approved by the FDA, either on its own or in combination with other compounds, so what is known about it comes from published Phase 2 and Phase 3 trial data rather than an approved drug label. This guide explains what cagrilintide is, how amylin signaling works in the body, why researchers pair it with semaglutide, what the trial data has found so far, how research material is handled and stored, and why none of this is a green light for personal use. It is written in plain language for anyone curious about the research, not as guidance for using cagrilintide on a person.

What Cagrilintide Is and Where It Comes From

In simple terms, here is what researchers are studying cagrilintide for:

• Appetite control. Helps people feel full for longer after eating and reduces how much they want to eat.
• Slower digestion. Slows down how quickly food leaves the stomach.
• Blood sugar balance. Helps smooth out blood sugar swings after meals.
• Simple dosing. Given as a single small injection under the skin, just once a week, which is more convenient than compounds that need daily dosing.

The technical details behind those effects:

• Cagrilintide is a synthetic analog of amylin, also called islet amyloid polypeptide, a 37-amino-acid hormone the pancreas releases alongside insulin.
• It is engineered to act for a long stretch of time and is dosed once weekly, unlike the natural hormone, which breaks down within minutes, and unlike pramlintide (brand name Symlin), an earlier amylin analog the FDA approved in 2005 that requires dosing before each meal.
• Small, deliberate tweaks to its amino acid building blocks are part of what let cagrilintide resist breakdown long enough for once-weekly dosing.
• Novo Nordisk developed cagrilintide mainly for weight management and, more recently, type 2 diabetes, studying it both on its own and alongside its GLP-1 compound semaglutide.
• Almost all of the current cagrilintide research centers on this metabolic pairing, rather than the inflammation or tissue-repair research directions covered elsewhere on this site.

Cagrilintide sits in a broader family of metabolic research compounds that also includes GLP-1 agonists like semaglutide and multi-hormone agonists like tirzepatide and retatrutide, though it works through an entirely different hormone system than any of those. Where those compounds act on gut hormone receptors, cagrilintide’s target is the amylin pathway described below, which is why researchers frame it as a complement to the GLP-1 class rather than a direct substitute for it.

How Amylin Signaling Works in the Body

Amylin is released alongside insulin from specialized cells in the pancreas, in a natural ratio of roughly one hundred parts insulin to one part amylin. After a meal, it works alongside insulin to keep blood sugar from spiking, mainly by slowing how quickly food leaves the stomach, reducing appetite, and suppressing the release of glucagon, a hormone that would otherwise push blood sugar higher. Researchers sometimes describe amylin as insulin’s quieter partner, present at every meal but rarely discussed outside specialist literature.

Amylin was first isolated in 1987, and it took until 2005 for the first amylin-based compound, pramlintide, to reach FDA approval. That gap reflects how difficult amylin has been to work with outside the body, since the natural hormone tends to clump together and loses its function quickly once removed from its normal environment in the pancreas.

Because natural amylin breaks down within minutes, researchers have spent close to two decades building longer-lasting synthetic versions. Cagrilintide is the newest of these studied at scale. Researchers also compare it with a related class called dual amylin and calcitonin receptor agonists, compounds built to activate a second receptor alongside the amylin receptor. In animal studies, those dual-receptor compounds have sometimes produced larger weight and blood sugar effects than cagrilintide alone, a comparison researchers are watching closely.

Why Cagrilintide Is Paired With Semaglutide

Semaglutide, the GLP-1 compound covered in semaglutide vs tirzepatide, works through a different hormone pathway than cagrilintide, and pairing the two compounds is central to nearly all of the newest cagrilintide research.

GLP-1 medications were originally developed for type 2 diabetes and only later became widely known for weight loss. GLP-1 (short for glucagon-like peptide-1) is a hormone the intestine makes naturally, and semaglutide, the active ingredient in the FDA-approved products Wegovy, Ozempic, and Rybelsus, works by mimicking its effects:

• Insulin release. Prompts the pancreas to release insulin around mealtimes.
• Lower glucagon. Reduces the release of glucagon, a hormone that raises blood sugar.
• Slower stomach emptying. Slows how quickly the stomach empties, which slows digestion and blunts the rise in blood sugar after eating.
• Fullness signal. Creates a sense of fullness that can reduce appetite and how much someone eats.

Because amylin and GLP-1 signaling act on largely separate appetite and blood sugar pathways, combining the two compounds could, at least in principle, produce a larger effect than either one on its own, and that possibility is the central question the CagriSema trials are designed to test. The combination is often referred to in trial literature as CagriSema.

• Early proof of concept. In an early Phase 2 trial in people with type 2 diabetes, researchers tested cagrilintide 2.4 mg combined with semaglutide 2.4 mg, both dosed once weekly, to check whether the pairing was safe and effective before moving to larger trials.
• The REDEFINE program. Later Phase 3 trials expanded that testing to much larger groups: one trial in people with overweight or obesity without diabetes (REDEFINE 1), and one in people with overweight or obesity who also have type 2 diabetes (REDEFINE 2).
• REDEFINE 1 (68 weeks): the combination produced average weight loss of 20.4%, compared with 14.9% for semaglutide alone, 11.5% for cagrilintide alone, and 3.0% for placebo.
• REDEFINE 2 (68 weeks, type 2 diabetes): the combination produced average weight loss of 13.7%, compared with 3.1% for placebo.

Because CagriSema combines two compounds into one fixed weekly dose, regulators require evidence that the pairing adds a real benefit over either compound alone, which is exactly the comparison a newer Phase 3 trial called REIMAGINE 2 was designed to make.

• Who was studied. REIMAGINE 2 enrolled 2,728 people with type 2 diabetes not well controlled by metformin, an older diabetes medicine; about 40% were also taking an SGLT2 inhibitor, a type of diabetes medicine that helps the kidneys remove extra sugar through urine. Participants started the trial with an average body weight of 101 kg (about 223 lb).
• Full adherence to treatment: CagriSema 2.4/2.4 mg produced 14.2% weight loss and a 1.91 percentage point HbA1c reduction over 68 weeks, compared with 10.2% weight loss and a 1.76 point reduction on semaglutide 2.4 mg alone.
• Counting everyone, regardless of how closely they stuck to treatment: 12.9% weight loss on the combination compared with 9.2% on semaglutide alone.
• Novo Nordisk announced these results directly rather than publishing them in a peer-reviewed journal, and outside researchers have cautioned that manufacturer-reported early results still need independent confirmation.

Together, these results are why cagrilintide is rarely discussed on its own in the newest research: the combination with semaglutide consistently outperforms either compound by itself, which is the main reason CagriSema, rather than cagrilintide alone, has become the primary focus of the ongoing Phase 3 program. Novo Nordisk has also said further trials are planned comparing CagriSema directly against tirzepatide, the dual GLP-1/GIP compound covered elsewhere on this site.

What the Trial Data Has Found So Far

The earliest human evidence for cagrilintide comes from a Phase 2 dose-finding trial that tested five weekly doses, from 0.3 mg up to 4.5 mg, against both placebo and liraglutide, an older GLP-1 compound included for comparison.

• Weight loss across the five cagrilintide doses ranged from 6.0% to 10.8%, compared with 3.0% on placebo. The highest dose, 4.5 mg, edged out the liraglutide comparator, 10.8% versus 9.0%.
• Side effects. Gastrointestinal reports (nausea, constipation, and diarrhea) were the most common, and injection-site reactions (redness, itching, or swelling where the shot was given) were also frequently reported.
• How common: gastrointestinal reports occurred in roughly 41% to 63% of cagrilintide recipients across doses, compared with 32% on placebo; nausea specifically ranged from 20% to 47%, compared with 18% on placebo. Most of these effects were mild to moderate and tended to ease over time.

That side effect pattern, gastrointestinal complaints leading the list alongside injection-site reactions, has continued to show up in the later combination trials. A 2024 systematic review and meta-analysis pooled data across several of these trials and concluded that cagrilintide, both alone and combined with semaglutide, produced consistent weight loss findings, reinforcing the individual trial results described above rather than turning up a conflicting signal.

How Researchers Handle and Store Cagrilintide

Cagrilintide research material follows the same general handling conventions used across most peptide and peptide-like compounds on this site. It arrives as a freeze-dried powder that has to be reconstituted, or mixed with a liquid, before use in a research setting, typically with bacteriostatic water, a sterile saline solution formulated to resist bacterial growth across repeated draws from the same vial.

• After mixing. Reconstituted material is stored refrigerated and used within the window described in the relevant study or supplier documentation, since amylin analogs, like most peptides, break down faster once mixed into liquid form.
• Getting the ratio right. Vial size and target concentration determine how much diluent to add, a calculation covered step by step in how to reconstitute peptides.
• Before mixing. Freeze-dried cagrilintide is more stable than the reconstituted form and should be kept according to the supplier’s storage instructions until it is prepared for research use.
• Combining with semaglutide. Because the two compounds are studied separately rather than mixed into a single vial in most published trials, research protocols that combine them typically involve reconstituting and dosing each one on its own, with its own concentration calculation and storage window.

Why This Stays Research Use Only

Cagrilintide also carries some of the same class-wide cautions seen with other amylin- and GLP-1-adjacent compounds, based on the trial and safety literature so far:

• Thyroid tumors. A caution around thyroid C-cell tumors (tumors in a specific type of thyroid cell), based on animal studies rather than confirmed human cases, similar to the warning carried by GLP-1 compounds.
• Thyroid cancer history. Exclusion of anyone with a personal or family history of medullary thyroid carcinoma (a rare thyroid cancer) or a related condition called multiple endocrine neoplasia type 2 (MEN 2).
• Stomach conditions. Exclusion of anyone with gastroparesis (a condition where the stomach empties too slowly on its own), since cagrilintide’s own effect of slowing stomach emptying could make that condition harder to manage.
• Serious side effects have been rare across the trials published so far, but the overall safety record is still much smaller than for older, already-approved compounds.

In December 2025, Novo Nordisk submitted a New Drug Application to the FDA for CagriSema, seeking approval as a weight-management treatment alongside diet and exercise, the same use case semaglutide already has under the brand name Wegovy. As of this writing, that application has not been approved, and cagrilintide, whether alone or combined with semaglutide, remains fully investigational.

Research Use Only. This content is provided for Research Use Only (RUO). The compounds discussed are not drugs, dietary supplements, foods, or cosmetics, and are not intended for human or animal consumption, diagnostic use, or therapeutic use of any kind. They have not been evaluated by the FDA for safety or efficacy in humans. Any research use must be conducted by qualified professionals in a controlled laboratory environment, in accordance with all applicable institutional, local, and federal regulations. Cagrilintide has no approved label, either alone or in combination with semaglutide, so the figures above describe trial reporting for an investigational compound and are shared here as research background, not as a handling or dosing guide for any research material.

Frequently Asked Questions

What is cagrilintide?

Cagrilintide is a long-acting synthetic version of amylin, a hormone the pancreas releases alongside insulin. It is studied mainly for weight management and, more recently, type 2 diabetes, both on its own and combined with semaglutide.

Is cagrilintide the same as semaglutide?

No. Semaglutide is a GLP-1 compound that works through a different hormone pathway. Researchers study the two together, often called CagriSema in the trial literature, to see whether combining them produces a larger effect than either compound alone.

Is CagriSema approved by the FDA?

Not yet. Novo Nordisk submitted a New Drug Application for CagriSema in December 2025, but as of this writing the FDA has not made a decision, and cagrilintide alone remains investigational as well.

Is cagrilintide legal?

Cagrilintide is not approved by the FDA for any medical use and is sold for research use only. Its regulatory status may change as more trial data is published, so current rules should always be checked directly rather than assumed.

Why do cagrilintide trials measure both weight loss and blood sugar control?

Because cagrilintide is studied both as a weight-management compound and, alongside semaglutide, as a type 2 diabetes compound, trials track whichever outcomes match the population enrolled, sometimes both in the same study.

Sources

1. Davies MJ, et al. (2025). Cagrilintide-Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes. New England Journal of Medicine.
2. Garvey WT, et al. (2025). Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine.
3. Lau DCW, et al. (2021). Once-Weekly Cagrilintide for Weight Management in People With Overweight and Obesity, a Multicentre, Randomised, Double-Blind, Placebo-Controlled and Active-Controlled, Dose-Finding Phase 2 Trial. The Lancet.
4. Frias JP, et al. (2023). Efficacy and Safety of Co-Administered Once-Weekly Cagrilintide 2.4 mg With Once-Weekly Semaglutide 2.4 mg in Type 2 Diabetes, a Multicentre, Randomised, Double-Blind, Active-Controlled, Phase 2 Trial. The Lancet.
5. Kruse T, et al. (2021). Development of Cagrilintide, a Long-Acting Amylin Analogue. Journal of Medicinal Chemistry.
6. Dutta D, et al. (2024). Efficacy and Safety of Cagrilintide Alone and in Combination With Semaglutide (Cagrisema) as Anti-Obesity Medications, a Systematic Review and Meta-Analysis. Indian Journal of Endocrinology and Metabolism.

Research compounds referenced above, including semaglutide, are stocked in the weight loss category, alongside the rest of the shop.